Compugen’s IND for COM503 in solid tumors cleared by FDA

Compugen (CGEN) announced that the FDA has cleared the investigational new drug – IND – application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead Sciences (GILD). The IND clearance triggered a $30M milestone payment from Gilead and Compugen is on track to initiate the Phase 1 trial in solid tumors in Q4.